Regulatory mechanism of CCN2 production by serotonin via 5-HT.sub.2A and 5-HT.sub.2B receptors in chondrocytes

Serotonin (5-hydroxytryptamine: 5-HT) is recognized as a neurotransmitter in the central nerve system and as a regulator of systemic blood pressure in the peripheral tissues. Recently, it was reported that 5-HT.sub.2 receptors (5-HT.sub.2 Rs) were expressed in cartilage tissues lacking both vessels...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2017-11, Vol.12 (11), p.e0188014
Hauptverfasser: Hori, Ayaka, Nishida, Takashi, Takashiba, Shogo, Kubota, Satoshi, Takigawa, Masaharu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Serotonin (5-hydroxytryptamine: 5-HT) is recognized as a neurotransmitter in the central nerve system and as a regulator of systemic blood pressure in the peripheral tissues. Recently, it was reported that 5-HT.sub.2 receptors (5-HT.sub.2 Rs) were expressed in cartilage tissues lacking both vessels and neurons, suggesting possible novel functions of 5-HT during cartilage development and regeneration. Our previous data indicated that CCN family protein 2/connective tissue growth factor (CCN2/CTGF) plays a central role in cartilage development and regeneration. Therefore, the aim of this study was to investigate the effect of 5-HT on the production of CCN2 in chondrocytes. Firstly, we showed that the mRNAs of 5-HT.sub.2 R subtypes 5-HT.sub.2A R and 5-HT.sub.2B R, were expressed in a human chondrocytic cell line, HCS-2/8; however, 5-HT.sub.2C R mRNA was not detected. In addition, exogenously added 5-HT did not affect the 5-HT.sub.2A R and 5-HT.sub.2B R expressions. Next, we demonstrated that CCN2 production was increased by treatment with a 5-HT.sub.2A R agonist and the combination of 5-HT and 5-HT.sub.2B R antagonist. In contrast, treatment with a 5-HT.sub.2B R agonist and the combination of 5-HT and 5-HT.sub.2A R antagonist decreased CCN2 production. Furthermore, we showed that phosphorylation of Akt and p38 MAPK were increased by treatment with 5-HT.sub.2A R agonist, and that phosphorylation of PKC[epsilon], PKC[zeta], ERK1/2 and JNK were increased by treatment with 5-HT.sub.2B R agonist. Finally, we found that 5-HT.sub.2A R was localized in the growth plate, whereas 5-HT.sub.2B R was localized in the articular cartilage. These findings suggest that 5-HT promotes CCN2 production through the 5-HT.sub.2A R in growth plates, and that it represses CCN2 production through the 5-HT.sub.2B R in articular cartilage for harmonized development of long bones.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0188014